4-(5-(4-氯苯基)-3-(三氟甲基)-1H- CAS#: 170569-86-5

4-(5-(4-氯苯基)-3-(三氟甲基)-1H-

生物活性靶点体外研究体内研究用途与合成方法 MSDS 4-(5-(4-氯苯基)-3-(三氟甲基)-1H-价格(试剂级) 上下游产品信息

中文名称	4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
中文同义词	4-(5-(4-氯苯基)-3-(三氟甲基)-1H-;4-(5-(4-氯苯基)-3-(三氟甲基)-1H-吡唑-1-基)苯磺酰胺;4-(5-(4-氯苯基)-3-(三氟甲基)-1H-,10 MM DMSO 溶液
英文名称	4-[5-(4-Chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
英文同义词	4-[5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOL-1-YL]BENZENESULFONAMIDE;SC-58236;Benzenesulfonamide, 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-;SC 236 - SC 58236;SC-236,gastric,PPAR,cancer,ischemia,Liver,inhibit,allodynia,Inhibitor,fibrogenesis,neuroprotection,COX,Cyclooxygenase,Apoptosis,TNF-α,Peroxisome proliferator-activated receptors,fibrosis,SC236;SC-236, 10 mM in DMSO;SC-236;4-[5-(4-Chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
CAS号	170569-86-5
分子式	C16H11ClF3N3O2S
分子量	401.79
EINECS号
相关类别	Amines;Apoptosis;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pfizer compounds;Pharmaceuticals
Mol文件	Mol File
结构式

4-(5-(4-氯苯基)-3-(三氟甲基)-1H- 性质

熔点	146-148°C
沸点	543.4±60.0 °C(Predicted)
密度	1.54±0.1 g/cm3(Predicted)
储存条件	2-8°C
溶解度	二甲基亚砜：>20mg/mL
形态	粉末
酸度系数(pKa)	9.66±0.10(Predicted)
颜色	白色至类白色
InChI	1S/C16H11ClF3N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)
InChIKey	NSQNZEUFHPTJME-UHFFFAOYSA-N
SMILES	NS(=O)(=O)c1ccc(cc1)-n2nc(cc2-c3ccc(Cl)cc3)C(F)(F)F

4-(5-(4-氯苯基)-3-(三氟甲基)-1H- 用途与合成方法

生物活性

SC-236 是具有口服活性的 COX-2 特异性抑制剂 (对 COX-1 的 IC50 值为 10 nM)和 PPARγ 激动剂。SC-236 可通过 c-Jun 氨基端抑制激活蛋白-1 (AP-1) 活性。SC-236在小鼠模型中通过抑制 ERK 的磷酸化发挥抗炎作用。

靶点

COX-2

10 nM (IC ₅₀ )

COX-1

17.8 μM (IC ₅₀ )

体外研究

SC-236 (15 μM, 30 min) suppresses the side effects of NSAIDs and prevented inflammation in vECs subjected to ALSS.
SC-236 significantly induces PPARγ expression in HSCs and acted as a potent PPARγ agonist in a luciferase-reporter trans-activation assay.
SC-236 strongly inhibits, in a time- and concentration-dependent manner, macrophage viability.
SC-236, either alone or in combination with 15d-PGJ2, induced a marked pro-apoptotic effect in HSCs in culture.
SC-236 mediates antitumor effect by modulation of AP-1-signaling pathway.

Western Blot Analysis

Cell Line:	vECs.
Concentration:	15 μM
Incubation Time:	30 min.
Result:	Showd significant reduction in COX-2 level and increase in IκBα level, thus preventing ALSS-induced NFκB activation and inflammation in vECs.

Western Blot Analysis

Cell Line:	COS 7 cells.
Concentration:	3 and 10 μM.
Incubation Time:	18 h (combined with 15d-PGJ ₂ ).
Result:	Acted in a concentration-dependent manner as a PPARγ agonist.

体内研究

SC-236 (6 mg/kg, gavage) exhibits anti-fibrotic properties in CCl4- treated animals.

Animal Model:	Seventy-six male adult Wistar rats weighing 200-220 g (CCl ₄ -treated).
Dosage:	6 mg/kg.
Administration:	Orally, 3 times per week.
Result:	A marked induction of COX-2 protein expression was detected by immunohistochemistry in the liver of CCl4-treated rats. Significantly reduced the degree of liver fibrosis. Dramatically suppressed α-SMA expression in CCl4-treated rats.

安全信息

危险品标志	T
危险类别码	25
安全说明	45
危险品运输编号	UN 2811 6.1 / PGIII
WGK Germany	3
存储类别	6.1C - 可燃，急性毒性类别3 毒性化合物或者引起慢性影响的化合物
危险性类别	急性毒性类别3经口

MSDS信息

4-(5-(4-氯苯基)-3-(三氟甲基)-1H- 价格(试剂级)

更新日期	产品编号	产品名称	CAS号	包装	价格
2026/09/15	HY-W010983	4-(5-(4-氯苯基)-3-(三氟甲基)-1H- SC-236	170569-86-5	5mg	477元
2026/09/15	HY-W010983	4-(5-(4-氯苯基)-3-(三氟甲基)-1H- SC-236	170569-86-5	10mM * 1mLin DMSO	524元

4-(5-(4-氯苯基)-3-(三氟甲基)-1H-